IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?
LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatric disorders. Continue Reading
YENOM NOTICIAS
Qué está moviendo el mercado.
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer
LB Pharmaceuticals Inc NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies t…
Top Biotech Gainers: SPRC On Watch, AVTR, NEO Boost Full-Year Outlook, SMTI Scooped Up
(RTTNews) - Today's top biotech gainers include SciSparc, after its subsidiary successfully completed internal validation of a proprietary quantum sampling platform designed to analyze clinical trial data; Avantor, following the release of…
Biotech Stocks At 52-Week Highs - INCY Rises With Q2 Results, PLSE, SI, BVS, LBRX
(RTTNews) - The following biotech stocks reached a 52-week high on July 28, 2026, driven by key catalysts including positive quarterly results. Incyte Corporation (INCY) Incyte is a biopharmaceutical company primarily engaged in discoverin…
Biotech Stocks At 52-Week Highs - ADVB Surges +73%, BLFS Rises After Acquisition, FBRX, SLN, LBRX
(RTTNews) - The following biotech stocks reached a 52-week high on July 22, 2026, driven by key catalysts including prospective clinical trial results and announced acquisitions. Advanced Biomed Inc. (ADVB) Advanced Biomed is a biotechnolo…
Top Biotech Gainers: ZCMD Surges 190%, LABT Advances On Nu-3 Progress, ARWR Hits The Targets
(RTTNews) - Today's top gainers in the healthcare sector include Zhongchao, surging more than 190%; Lakewood-Amedex, advancing on positive antimicrobial drug progress; Arrowhead, delivering encouraging severe hypertriglyceridemia trial res…
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), today announced that it has granted to Christopher Zergebel, the new Senior Vice President, Clinical Operations of L…
LB Pharmaceuticals Inc. (LBRX) Maintains Buy Rating as Analyst Highlights LB-102 Potential
We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. LB Pharmaceuticals Inc. (NASDAQ:LBRX) is one of the best up and coming stocks on our list. TheFly reported on May 28 that Clear Street maintained a B…
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
Key Points Nan Fung Group Holdings sold 163,957 Oculis (OCS) shares in Q1 2026, with an estimated transaction value of $4.3 million. After the sale, Nan Fung's remaining stake of 350,745 shares was valued at approximately $9.3 million -- r…
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
What happened According to a recent SEC filing, Nan Fung Group Holdings Ltd reduced its position in Oculis(NASDAQ:OCS) by 163,957 shares during the first quarter of 2026. The estimated value of the trade was $4.3 million, based on the quar…
LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression Published results from the Phase 2 NOVA-1 trial of LB-102 in schizophrenia in Th…
LB Pharmaceuticals Reports Positive Phase 2 Results For LB-102 Published In JAMA Psychiatry
(RTTNews) - LB Pharmaceuticals Inc's (LBRX) investigational therapy LB-102 has drawn fresh attention after results from its Phase 2 NOVA-1 trial- showing statistically significant benefit at all doses- were published in JAMA Psychiatry, un…
LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive…
Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight
The bipolar depression market is anticipated to increase during the forecast period (2026–2036), owing to the rise in the launch of emerging therapies such as Azetukalner (Xenon Pharmaceuticals), Elunetirom (ABX-002) (Autobahn Therapeutics…
LB Pharmaceuticals to Participate in Upcoming March Investor Events
NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive…
LB Pharmaceuticals Announces $100.0 Million Private Placement
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other n…
LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and ot…
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Dec. 10, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that it has granted to Kaya Pai Panandiker, the new Chief Commercial Officer of LB Pharmaceuticals, a…
LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the Company has been included in the Russell 2000® Index and the broad-market Russell 3000® Index, ef…
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that it has granted to James Rawls, the new Senior Vice President of Regulatory Affairs of LB Pharmac…
LB Pharmaceuticals Announces Presentation at the Stifel 2025 Healthcare Conference
NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that Heather Turner, Chief Executive Officer, will present at the Stifel 2025 Healthcare Conference i…
LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs
NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the appointment of James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs. Throughout…
LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms
NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that three posters featuring new and previously reported analyses from its Phase 2 NOVA1 clinical tri…
LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the appointments of William Kane and Rekha Hemrajani to its Board of Directors effective as of the p…
Wednesday 9/17 Insider Buying Report: LBRX, RAPP
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. On Friday, LB Pharmaceuticals', Ran Nussbaum,…
LB Pharmaceuticals tops 2025 biotech IPO list with $285m Nasdaq debut
US-based biotech LB Pharmaceuticals has broken the 2025 biotech initial public offering (IPO) drought – and with style – raising $285m via a public listing on the US stock market. The company, which is developing treatments for schizophren…
Schizophrenia drug developer LB Pharma jumps in trading debut
Worawith Ounpeng/iStock via Getty Images LB Pharmaceuticals (LBRX [https://seekingalpha.com/symbol/LBRX]) climbed ~26% on Thursday as the New York-based biopharma, focused on developing drugs for neurological conditions such as schizophren…
Neuro drug maker LB Pharmaceuticals raises $285 million in U.S. IPO
[Business professional working on a laptop with an IPO (Initial Public Offering) digital graphic overlay. Suitable for finance, stock market, investment, and corporate growth visuals.] Biopharmaceutical company developing treatment for sch…
LB Pharmaceuticals Announces Pricing of its Upsized Initial Public Offering
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals”) today announced the pricing of its upsized initial public offering of 19,000,000 shares of its common stock at a public offering price of $15.00 per…
LB Pharmaceuticals raises $285M in first major biotech IPO since February
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. LB Pharmaceuticals raised $285 million in an initial public offering on Wednesday, marking th…
Neuro drug developer LB Pharma seeks $300M+ valuation in U.S. IPO
[Wooden blocks with the word IPO and virtual stock graph. Initial Public Offering or stock launch concept.] fadfebrian LB Pharmaceuticals (LBRX [https://seekingalpha.com/symbol/LBRX]), a drug developer focused on neuropsychiatric diseases…
Neuropsychiatric drug developer LB Pharma files for U.S. IPO
Worawith Ounpeng LB Pharmaceuticals (LBRX [https://seekingalpha.com/symbol/LBRX]), a New York-based drug developer focused on neuropsychiatric diseases, such as schizophrenia, has submitted regulatory filings with the Securities and Exchan…